Capelli, I.; Ribichini, D.; Provenzano, M.; Vetrano, D.; Aiello, V.; Cianciolo, G.; Vicennati, V.; Tomassetti, A.; Moschione, G.; Berti, S.;
et al. Impact of Baseline Clinical Variables on SGLT2i’s Antiproteinuric Effect in Diabetic Kidney Disease. Life 2023, 13, 1061.
https://doi.org/10.3390/life13041061
AMA Style
Capelli I, Ribichini D, Provenzano M, Vetrano D, Aiello V, Cianciolo G, Vicennati V, Tomassetti A, Moschione G, Berti S,
et al. Impact of Baseline Clinical Variables on SGLT2i’s Antiproteinuric Effect in Diabetic Kidney Disease. Life. 2023; 13(4):1061.
https://doi.org/10.3390/life13041061
Chicago/Turabian Style
Capelli, Irene, Danilo Ribichini, Michele Provenzano, Daniele Vetrano, Valeria Aiello, Giuseppe Cianciolo, Valentina Vicennati, Alessandro Tomassetti, Ginevra Moschione, Sabrina Berti,
and et al. 2023. "Impact of Baseline Clinical Variables on SGLT2i’s Antiproteinuric Effect in Diabetic Kidney Disease" Life 13, no. 4: 1061.
https://doi.org/10.3390/life13041061
APA Style
Capelli, I., Ribichini, D., Provenzano, M., Vetrano, D., Aiello, V., Cianciolo, G., Vicennati, V., Tomassetti, A., Moschione, G., Berti, S., Pagotto, U., & La Manna, G.
(2023). Impact of Baseline Clinical Variables on SGLT2i’s Antiproteinuric Effect in Diabetic Kidney Disease. Life, 13(4), 1061.
https://doi.org/10.3390/life13041061
